newsfilter
← Latest News
PR Newswire·

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FBLG
  • FibroBiologics, Inc. announced the USPTO issuance of U.S. Patent No. 12,716,055 for treating disc degenerative disease & stimulating proteoglycan synthesis.
  • The patent covers methods using fibroblast cells cultured with opioid receptor antagonists & toll-like receptor agonists to increase regenerative growth factor production.
  • Conditioned media & components derived from these stimulated fibroblasts can be delivered directly into discs or systemically to promote regeneration without invasive surgery.
  • The approach aims to address the unmet need for therapies that repair disc function rather than merely managing chronic back pain symptoms.
  • FibroBiologics now holds 270+ issued & pending patents across clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity, & cancer.